The antimicrobial peptides (AMP) produced by intestinal epithelial cells (IEC) play crucial roles in the regulation of intestinal homeostasis by controlling microbiota. Gut microbiota has been shown to promote IEC expression of RegIIIc and certain defensins. However, the mechanisms involved are still not completely understood. In this report, we found that IEC expression levels of RegIIIc and b-defensins 1, 3, and 4 were lower in G protein-coupled receptor (GPR)43 À / À mice compared to that of wild-type (WT) mice. Oral feeding with short-chain fatty acids (SCFA) promoted IEC production of RegIIIc and defensins in mice. Furthermore, SCFA induced RegIIIc and b-defensins in intestinal epithelial enteroids generated from WT but not GPR43 À / À mice. Mechanistically, SCFA activated mTOR and STAT3 in IEC, and knockdown of mTOR and STAT3 impaired SCFA induction of AMP production. Our studies thus demonstrated that microbiota metabolites SCFA promoted IEC RegIIIc and b-defensins in a GPR43-dependent manner. The data thereby provide a novel pathway by which microbiota regulates IEC expression of AMP and intestinal homeostasis.
INTRODUCTION
In spite of being home to a diverse community of large numbers of indigenous microorganisms, host intestines live in harmony with microbiota under homeostatic conditions. Among multiple mechanisms involved in the regulation of host responses to microbiota in maintaining intestinal homeostasis, antimicrobial peptides (AMP) that are produced by intestinal epithelial cells (IEC) and Paneth cells serve as the first line of defense against microbiota and occasionally pathogens. 1, 2 AMP regulate host responses to microbiota and are involved in the maintenance of intestinal homeostasis. Several distinct families of AMP have been identified including defensins, cathelicidins, and C-type lectins (such as the regenerating islet-derived protein (REG) family). AMP function to kill or inactivate microorganisms rapidly through different mechanisms. 1, 2 The spectrum of antimicrobial activity varies for each particular AMP. In general, defensins affect both Grampositive and Gram-negative bacteria and, in some cases, fungi, viruses, and protozoa. 3 RegIIIg, on the other hand, is selective for Gram-positive bacteria. 4 Mutually, gut microbiota may also differentially regulate AMP production. For example, although expression of a-defensins is independent of gut microbiota, the expression of RegIIIg is virtually absent in germ-free (GF) mice and increased upon re-colonization with gut microbiota. 4, 5 How microbiota promotes the expression of AMP remains unclear. In mice deficient in MyD88, an adapter molecule common to most Toll-like receptors (TLRs), IEC expression levels of RegIIIg and RegIIIb are decreased compared to that in wild-type (WT) mice, suggesting that IEC can directly sense bacteria through TLRs and promote the expression of RegIIIg and RegIIIb. 6, 7 In addition, innate lymphoid cell (ILC) production of IL-22 has also been shown to promote IEC expression of RegIIIg messenger RNA (mRNA). Notably, microbiota drives IL-22 production in ILCs, as demonstrated by the low levels of IL-22 produced by ILCs from GF mice. 8 Thus, gut microbiota can regulate AMP expression, at least partially, through interaction with IEC TLRs or stimulating ILC IL-22 production.
Accumulating evidence indicates that the host immune system can sense gut bacterial metabolites in addition to TLR ligands. Recognition of these small molecules greatly impacts the host immune response. 9, 10 Among gut microbiota metabolites, shortchain fatty acids (SCFA), which are solely metabolized from indigestible carbohydrates by intestinal bacteria, 11 have been shown to have immense impact on the host. 12 Intact production of SCFA is associated with a reduced risk of different diseases, including inflammatory bowel diseases (IBD). As the most abundant SCFA, acetate, propionate, and butyrate are present in the colonic lumen of humans at high concentrations, ranging from 50 to 150 mM. 11, 13 SCFA can function through the activation of mammalian G protein-coupled receptors (GPCR). 14 GPR41 and GPR43 are two major host receptors for most SCFA. 15 SCFA can also inhibit histone deacetylase activity (HDAC) to downregulate macrophage pro-inflammatory cytokine production and activate peroxisome proliferator-activated receptor g to stimulate human colonic epithelial cell expression of angiopoietin-like protein 4. 16, 17 In addition, SCFA promote intestinal Treg cell development which is probably also mediated by their HDAC inhibitor activity but independent of GPR43, although it is still debatable as conflicting data have been published. 10, 18, 19 SCFA butyrate has been demonstrated to induce LL-37/ hCAP18, a member of cathelicidin family, in various human colon cell lines. 20 However, the underlying molecular mechanisms by which SCFA regulate IEC AMP production are still not completely understood. It has been reported that MAP kinases respond differently to butyrate stimulation. 21 The MEK-ERK pathway regulates butyrate-induced LL-37 expression, whereas p38/MAP kinase exhibits little effect on AMP production. 21, 22 C-Jun N-terminal kinase (JNK) also positively regulates cathelicidin production in tissue epithelial cells. 23 The current study was undertaken to investigate the mechanisms of AMP production induced by SCFA. Here, we report that SCFA promoted RegIIIg and b-defensin expression in IEC through GPR43, which is mediated by mammalian target of rapamycin (mTOR) and signal transducers and activator of transcription 3 (STAT3).
RESULTS
Expression of RegIIIc and b-defensins in IEC is impaired in GPR43 À / À mice It has been previously reported that microbiota regulates IEC AMP expression differentially. 4, 5 As microbiota-derived SCFA can modulate IEC activity through GPR43, we investigated whether GPR43 regulates AMP expression in IEC. We Figure 1 Decreased production of RegIIIg and b-defensins in IEC of GPR43 À / À mice. IEC from small intestine were isolated from WT and GPR43 À / À mice respectively. (a) IEC expression of RegIIIg and b-defensins 1, 3, and 4 in GPR43 À / À and WT mice was determined by qRT-PCR and normalized against gapdh. Pooled data from two independent experiments. n ¼ 5 mice/group. (b) Protein levels of RegIIIg and b-defensins were determined by western blot. Data are reflective of two independent experiments. n ¼ 4 mice/group. (c) Protein/b-actin relative expression levels of RegIIIg and bdefensins were compared between GPR43 À / À and WT mice. Data were combined from two independent experiments. *Po0.05; **Po0.01. IEC, intestinal epithelial cell; qRT-PCR, quantitative real-time polymerase chain reaction; WT, wild type. measured the expression of RegIIIg and b-defensins 1, 3, and 4 in C57BL/6 (WT) and GPR43 À / À mice at both RNA and protein levels. Quantitative real-time polymerase chain reaction (qRT-PCR) revealed that the transcription of RegIIIg and b-defensin 1, 3, 4 mRNA was compromised in GPR43 À / À IEC compared to the WT control ( Figure 1a ). Consistent with gene expression studies, protein levels of RegIIIg and b-defensin 1, 3, 4 in GPR43 À / À mice were significantly lower compared to WT mice (Figure 1b,c) . Collectively, these data indicated that SCFA recognition by GPR43 promotes IEC production of RegIIIg and b-defensins.
Feeding SCFA promotes IEC expression of RegIIIc and bdefensins in WT but not GPR43 À / À mice As the most potent agonists for GPR43, SCFA play critical roles in intestinal barrier function. 24, 25 Butyrate, in particular, has been demonstrated to induce cathelicidin AMP and b-defensin 1 in human lung epithelial cells. 23 We thus investigated whether SCFA can elicit a similar effect on IEC, and whether GPR43 mediates such effects. Because gut microbiota produces high levels of SCFA in the intestines which may confound the data interpretation, we first treated mice with broad-spectrum antibiotics for 10 days to eliminate gut microbiota as well as their metabolites SCFA, followed by 21 days of butyrate and antibiotics administration in drinking water. Intestinal epithelial cells were then isolated and assessed for AMP expression. We found decreased expression of RegIIIg, but no significant difference of b-defensins in mice receiving antibiotics compared to the control mice (Supplementary Figure S1 online). As expected, in WT mice, feeding butyrate enhanced the expression of RegIIIg and b-defensin 1, 3, and 4 compared to controls in IEC (Figure 2a ). Increased protein levels of RegIIIg and b-defensins were also detected by western blot (Figure  2b ,c). Feeding butyrate also increased expression of cathelicidin-related antimicrobial peptide (CRAMP) ( Figure  2a ). Additionally, mice fed with acetate slightly increased expression of RegIIIg and b-defensins in IEC compared to control (Supplementary Figure S2 ). However, feeding butyrate did not affect the expression of RegIIIg and bdefensin 1, 3, and 4 in IEC of GPR43 À / À mice ( Figure 2d ). Together, these data suggested that SCFA serve as potent inducers of AMP production by IEC, which is mediated by GPR43.
We then investigated whether GPR43 and feeding butyrate affect gut microbiota, which could potentially mediate butyrate induction of AMP production. We fed WT and GPR43 À / À mice with 300 mM butyrate for 21 days, and gut microbiota assessed by 16s ribosomal ribonucleic acid (rRNA) pyrosequencing of fecal samples. In GPR43 À / À mice, the abundance of families of Prevotellaceae, Erysipelotrichaceae, and Alcaligenaceae was decreased compared to WT mice (Figure 3b) . At genus level, Alistipes and Lactobacillus were increased while Alloprevotella, Blautia, and Odoribacter were decreased (Figure 3c ), indicating that GPR43 signaling regulated gut microbiota composition. Feeding WT mice butyrate resulted in deviation of the microbial population toward an increased proportion of Bacteroidetes phylum (54.7-64.2%, including Prevotellaceae, P ¼ 0.06) but decreased proportion of Proteobacteria phylum (7.3-4.0%, including Helicobacteraceae and Alcaligenaceae, P ¼ 0.05) and Firmicutes phylum (31.4-25.5%, including Lachnospiraceae and Erysipelotrichaceae) ( Figure  3a ). However, in GPR43 À / À mice, the increased proportion of Bacteroidetes phylum by feeding butyrate was decreased (from 51 to 55%) compared with WT mice. Furthermore, butyrate did not affect proportion of Proteobacteria phylum in GPR43 À / À mice. We also found that butyrate feeding increased the abundance of Prevotellaceae family but decreased the abundance of Alcaligenaceae family in WT mice but not in GPR43 À / À mice (Figure 3b) . At genus level, butyrate feeding increased abundance of Alloprevotella and Odoribacter but decreased abundance of Blautia and Lactobacillus in WT mice but not in GPR43 À / À mice ( Figure 3c ). However, in contrast to the mice treated with antibiotics ( Figure 2) , feeding butyrate without depletion of gut bacteria did not increase IEC expression of RegIIIg and b-defensins in both WT and GPR43 À / À mice (Supplementary Figure S3 ), possibly due to the high levels of pre-existing SCFA produced by gut microbiota in the intestines.
SCFA promote expression of RegIIIc and b-defensins in both mouse and human IEC in vitro in a restricted time window
To determine whether SCFA directly promote the IEC expression of AMP in vitro, we utilized IEC lines and examined RegIIIg and b-defensins expression after butyrate stimulation. We first used mouse small intestinal epithelial (MSIE) cells, a conditionally immortalized epithelial cell line that retains properties of primary IEC. 26 We treated MSIE cells with butyrate for 48 h and measured RegIIIg and b-defensins at both gene expression and protein levels. Treatment with butyrate significantly induced the expression of RegIIIg and b-defensin 1, 3, and 4 (Figures 4a,b). We then determined the kinetics of the butyrate-induced IEC expression of RegIIIg and bdefensins. We treated the MSIE cells with butyrate and measured RegIIIg and b-defensins with respect to time over the course of 72 h. Butyrate treatment did not induce expression of RegIIIg and b-defensins in early time points of 1-12 h. Their expression was slightly increased at 24 h, but did not reach significance. Consistently, the expression levels of RegIIIg and b-defensins were significantly increased at 48 h, but returned to levels similar to those in controls by 72 h (Supplementary Figure S4 ), indicating that butyrate stimulation occurs within a narrow time window. Treatment with GPR43 agonist elicited similar effect on RegIIIg and b-defensin 1, 3, and 4 expression ( Figure 4c ), indicating that GPR43 may mediate the butyrateinduced expression of RegIIIg and b-defensins in IEC.
To investigate if SCFA also regulate expression of AMP in human IEC, a human colonic epithelial cell line (HT-29) was stimulated with 0.5 mM butyrate for 48 h. Consistently, mRNA expression levels of RegIIIa, the human ortholog of mouse RegIIIg, b-defensin 1, and LL-37 were enhanced in butyratetreated HT-29 cells (Figure 5a ). However, butyrate did not affect the expression of a-defensin 5 and a-defensin 6 in HT-29 cells ( Figure 5a ). We also demonstrated a similar effect of acetate and propionate on HT-29 cells. While propionate induced mRNA expression of both RegIIIa and b-defensin 1, the expression of a-defensins remained unaffected. Acetate induced b-defensin 1 but not RegIIIa and a-defensins (Supplementary Figure S5) . Moreover, GPR43 agonist promoted HT-29 cell expression of RegIIIa, b-defensin 1, and LL-37 but not a-defensin 5 and a-defensin 6 ( Figure 5b ).
SCFA induce expression of RegIIIc and b-defensins in WT but not GRP43 À / À small intestinal epithelial enteroids
We next sought to determine if IEC expression of GPR43 directly mediates SCFA-induced AMP production. We established an ex vivo three-dimensional enteroid culture to recapitulate the comprehensive intestinal microenvironment. Enteroids were generated from WT and GRP43 À / À mice respectively, and treated with butyrate or PBS control for 48 h. Butyrate treatment did not affect the viability of enteroids as well as the expression of Mki67 (gene for proliferation) and
Lgr5 (gene for stemness) (Supplementary Figure S6 ). As shown in Figure 6 , butyrate treatment induced the expression of RegIIIg and b-defensin 1 in WT enteroids, whereas the effect was abrogated in GPR43 À / À organoids. These data confirmed that GPR43 mediates IEC production of RegIIIg and bdefensins induced by butyrate.
mTOR mediates SCFA induction of RegIIIc and b-defensins in IEC
The mTOR, an evolutionarily conserved integrative serinethreonine kinase, is a crucial regulator of physiology of various cells in response to environmental cues and nutrients. 27 mTOR functions through phosphorylating the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and p70 ribosomal S6 kinase 1 (S6K1). SCFA have been shown to activate mTOR in T cells and dendritic cells (DC). 13, 28 We thus investigated whether the mTOR pathway is involved in SCFA-induced RegIIIg and b-defensins production in IEC. We first treated MSIE cells with butyrate and measured mTOR activation by detecting both phosphorylated-mTOR (p-mTOR) and phosphorylated- Figure 7a , butyrate promoted the expression of p-mTOR and p-4EBP1. Consistently, we detected activation of S6K1 by flow cytometry in butyratetreated MSIE cells (Figure 7b) . Moreover, butyrate activation of mTOR signaling was via GPR43, as evidenced by the activation of mTOR downstream effector S6K1 by a GPR43 agonist (Supplementary Figure S7) . To determine that butyrateinduced mTOR activation contributes to IEC production of RegIIIg and b-defensins, we used mTOR siRNA to specifically knockdown mTOR. MSIE cells were transfected with mTOR siRNA or control non-targeting siRNA, with a transfection efficiency around 50% (Figure 7c) . The cells were then treated with butyrate. Knockdown of mTOR impaired butyrateinduced expression of RegIIIg and b-defensins at the levels of both mRNA (Figure 7d ) and proteins (Figure 8e) . Collectively, these data demonstrated that butyrate activates the mTOR pathway to positively regulate RegIIIg and bdefensins production in IEC.
4EBP1 (p-4EBP1). As shown in
STAT3 regulates butyrate promotion of RegIIIc and bdefensins production in IEC It has been shown that STAT3 is required for RegIIIg production in lung epithelium. 29 Likewise, it is also necessary for IL-22-induced RegIIIg and b-defensins production in human IEC and alveolar epithelium. [30] [31] [32] We postulated that STAT3 regulates SCFA induction of AMP production in IEC. Butyrate treatment led to activation of STAT3 in MSIE cells, evidenced by enhanced phosphorylation of STAT3 (Figure 8a) . Blockade of STAT3 using a specific STAT3 inhibitor HJC0152 33 greatly attenuated butyrate-induced RegIIIg and b-defensins mRNA expression ( Figure 8b) . Secondly, we knocked down STAT3 in MSIE cells with specific siRNA. The obtained transfection efficiency was about 50% (Figure 8c ). In accordance with the data of the STAT3 inhibitor, the knockdown of STAT3 resulted in decreased butyrate-induced IEC expression of RegIIIg and b-defensins at the levels of both mRNA and proteins ( Figure  8d,e ). Together, these data indicated that STAT3 is critical for the butyrate-induced AMP production in IEC.
DISCUSSION
The interplay between gut commensal bacteria and the host provides beneficial effects on host metabolism as well as immune regulation. [34] [35] [36] In this report, we have demonstrated that gut microbiota metabolites SCFA promoted IEC expression of RegIIIg and b-defensins 1, 3, and 4 through GPR43, essential for the maintenance of intestinal homeostasis.
Gut microbiota has been shown to be important for the production of certain AMP in the intestines, in that RegIIIg and certain b-defensins are virtually absent in GF mice. 4, 5 Mice lacking TLR ligands also displayed impaired production of RegIIIg and RegIIIb in IEC compared to WT mice, suggesting that microbiota can directly affect IEC AMP production through interaction with TLRs. 6, 7 However, substantial amounts of AMP have been detected in MyD88 À / À mice housed under specific pathogen free (SPF) conditions. [4] [5] [6] [7] This indicates the presence of multiple sensors and mechanisms for AMP regulation by microbiota, in addition to direct TLR-TLR ligand interactions. In the current report, we investigated whether SCFA regulated the IEC production of RegIII and the defensin family. Indeed, extraneous butyrate administration promoted IEC production of RegIIIg, b-defensin 1, 3, and 4, and CRAMP (Figure 2) . This was further supported by in vitro Figure 3 Butyrate feeding changes gut microbiota. WT and GPR43 À / À C57BL/6 mice were fed with 300 mM butyrate for 21 days. Gut microbiota prior and after feeding butyrate was determined by 16s rRNA sequencing. Bar charts for fecal bacterial composition of phylum level (a), family level (b), and genus level (c). N ¼ 4-5 mice/group. WT, wild type. studies using human and murine intestinal cell lines (Figures 4  and 5 ). Interestingly, a previous report showed that SCFA also promoted b-defensin expression in porcine IEC by using porcine IPEC-J2 IEC, 37 indicating that SCFA can function across different species to promote IEC expression of AMP.
It has been shown that SCFA bind cell-surface receptors such as GPR41, GPR43, and GPR109a. 13, 38 SCFA-GPR43 interaction has been reported in regulating intestinal inflammatory responses, 39 in that GPR43 À / À mice demonstrated exacerbated colitis after dextran sodium sulfate insult. 40 This further indicates that SCFA affects the intestine via the GPR43 receptor. More recently, it was discovered that low fiber diets induced and perpetuated intestinal inflammation, whereas high fiber diets protected against colitis. 41 The beneficial effect of high fiber intake derives from gut microbiota metabolic products, and subsequent SCFA binding to GPR43 and GPR109a in the intestines. Further studies revealed that SCFA activated the NLRP3 inflammasome through GPCR signaling, which conferred resistance to colitis. 41 Our data demonstrated that production of RegIIIg and b-defensins in IEC was impaired in GPR43 À / À mice (Figure 1) . Additionally, administration of a GPR43 agonist enhanced AMP production in both murine and human IEC, indicating that GPR43 is involved in AMP production. Furthermore, butyrate promoted expression of RegIIIg and b-defensins in WT but not in GPR43 À / À intestinal epithelial enteroids ( Figure 6) . SCFA, especially butyrate, have been shown as HDAC inhibitors, and butyrate-induced HDAC3 inhibition regulates IEC production of retinoic acid, which can potentially contribute to maintenance of intestinal homeostasis. 42 Our data do not rule out the involvement of HDAC inhibition in SCFA induction of AMP in IEC. It is very likely that SCFA regulate IEC function via multiple mechanisms.
mTOR is a key regulator in various physiological aspects. 43 Among different cell types, SCFA have been shown to activate mTOR in T cells and DCs. 27, 44 We showed that SCFA activated the mTOR pathway in IEC (Figure 7a ). Knockdown of mTOR attenuated SCFA-induced AMP production, indicating that activation of mTOR facilitated RegIIIg and b-defensins production in IEC. Interestingly, butyrate also activated STAT3, which has been implicated in the regulation of immune responses of both innate and adaptive immune cells in the intestines. 45 The blockade of STAT3 signaling compromised RegIIIg and b-defensins production in SCFAtreated IEC, suggesting that STAT3 is indispensable in SCFA induction of AMP production in IEC (Figure 8) . As activation of STAT3 impacts epithelial cell viability, it is very likely that SCFA activation of STAT3 supports intestinal organoid stemness proliferation, which will affect the AMP secretion by an indirect mechanism as well. Therefore, SCFA activation of mTOR and STAT3 could collaboratively promote AMP expression in IEC.
RegIIIg and b-defensins secreted by IEC are known for limiting bacteria and manipulating species composition, especially Grampositive species. Our findings that SCFA induce IEC RegIIIg and b-defensins production in IEC suggest a possible autoregulation of microbiota. In light of this, drugs targeting the intrinsic pathways of SCFA-mediated AMP production might serve as promising candidates for clinical applications by promoting host barrier defense and correcting dysbiosis, and restoring homeostatic balance. Nevertheless, the modification of AMP requires carefully monitoring, and dysregulated AMP production can have negative impacts on intestinal homeostasis. Indeed, it was discovered that excessive lipocalin-2 and calprotectin production induced by IL-22 can, in turn, suppress commensal bacteria, resulting in pathogen colonization. 46 In order to preserve intestinal homeostasis, critical elements of host immunity and microbial colonization need to counterbalance each other. To that end, we present evidence that metabolites from commensal microbiota are capable of inducing host innate immunity to regulate the intestinal environment.
Moreover, we demonstrated that GPR43 signaling regulated gut microbiota and feeding butyrate resulted in alterations in the composition of the microbiota (Figure 3) . Among the bacteria affected by GPR43 signaling, the abundance of Prevotellaceae was decreased in GPR43 À / À mice compared to WT mice. Feeding WT mice but not GPR43 À / À mice butyrate increased the abundance of Prevotellaceae. A recent report by Jiminez et al. demonstrated more potent effects of butyrate on gut microbiota by rectal administration of 140 mM butyrate, especially when mice developed colitis upon infection with Citrobacter rodentium. 47 The difference of the data between Jiminez et al. and our current study is likely due to the different routes of butyrate administration. While butyrate by rectal administration would mostly go to the colon, due to potential absorption, only a small portion of oral administered butyrate would reach the intestinal lumen to affect gut microbiota. Even so, in consistent with our results, their study also demonstrated an increased proportion of Bacteroidetes phylum but decreased Firmicutes phylum after rectal administration of butyrate. 47 While our data demonstrated that butyrate promotes IEC AMP production, which can in turn affects microbiota composition, direct antimicrobial effects of butyrate have also been reported, 48 both of which can contribute to butyrate-induced microbiota alterations. Whether these changes directly or indirectly affect butyrate regulation of IEC expression of AMP cannot be stated at this point; however, we showed that SCFA-producing phyla were altered by feeding butyrate. While the Bacteroidetes phylum, which produces mainly acetate and propionate, was increased, members of the Firmicutes phylum, which preferentially produce butyrate, 49 were decreased. Thus, we are still not clear, at this point, whether and at what levels the butyratemediated alternations of gut microbiota contribute to butyrate induction of IEC AMP expression.
METHODS
Mice. C57BL/6 mice were purchased from the Jackson Laboratory and housed in the Animal Resource Center at University of Texas Medical Branch (UTMB). GPR43 À / À (Ffar2 tm1Lex ) mice were obtained from Bristol-Myers Squibb and maintained in the Animal Resource Center at UTMB. All experiments were reviewed and approved by the Institutional Animal Care and Use Committees of UTMB.
Reagents. OPTI-MEM were purchased from Life Technologies. GPR43 agonist (phenylacetamide agonist #44, Amgen) 50 was kindly provided by Dr Warren N. D'Souza, Amgen. STAT3 inhibitor HJC0152 was kindly provided by Dr Jia Zhou, University of Texas Medical Branch. McCoy's 5A and Lipofectamine RNAiMAX Transfection Reagent were purchased from Thermo Fisher Scientific. Sodium butyrate (MKBZ0227V), sodium propionate (SLBL9015V), and sodium acetate (SLBH4840V) were purchased from Sigma-Aldrich. Predesigned siRNA directed against mouse mTOR (SI01005683), STAT3 (SI01435287), and negative control siRNA (1027310) were purchased from Qiagen. Antibodies against phosphor-STAT3 (Tyr705), phosphor-mTOR (S2448), SCFA treatment. Mice were given drinking water containing 1 g l À 1 metronidazole (Sigma-Aldrich, St. Louis, MO), 0.5 g l À 1 vancomycin (Hospira, Lake Forest, IL), 1 g l À 1 ampicillin (Sigma-Aldrich), and 1 g l À 1 kanamycin (Fisher Scientific, Waltham, MA) for 10 days, followed by SCFA feeding. Butyrate or acetate was added to drinking water with a final concentration of 300 mM. Mice were sacrificed 21 days later for subsequent studies.
Isolation of IEC. After cleaning, small intestines were sliced into small pieces (o0.5 cm) and incubated with 5 mM EDTA in HBSS buffer containing% FBS at 37 1C for 40 min. Cells were collected by passaging supernatant through a 100-mM cell strainer (BD Falcon, Fremont, CA). After washing with PBS, IEC were separated from a 20/40% Percoll interface (Amersham Pharmacia Biotech, Amersham, UK).
Epithelial cell culture. MSIE cells 26 were maintained in RPMI 1640 medium with 5 U ml À 1 murine IFNg, ITS (5 mg ml À 1 insulin, 5 mg ml À 1 transferrin, and 5 ng ml À 1 selenous acid), 100 U ml À 1 penicillin/streptomycin, and 5% FBS at 33 1C and 5% CO 2 . After reaching 80% confluence, cells were starved at 37 1C for 16 h before subsequent experiments. HT-29 cells were cultured in complete McCoy's 5A Medium with 10% FBS at 37 1C and 5% CO 2 . siRNA transfection. siRNA transfection in MSIE cells was performed by using Lipofectamine RNAiMAX Transfection Reagent according to the manufacturer's instructions. Briefly, 3 Â 10 5 MSIE cells were incubated with 50 nM siRNA and 10 ml Lipofectamine RNAiMAX Transfection reagent in 1 ml OPTI-MEM medium for 6 h at 33 1C, followed by normal growth medium for 40 h at 33 1C. MSIE cells were then starved for 6 h at 33 1C before treatment. Transfection efficiency was determined at 40 h post transfection. The expression levels of RegIIIg and b-defensins were determined at 48 h after administration with SCFA.
Flow cytometry. MSIE cells were treated with SCFA for 48 h then stained for Live/Dead dye and phospho-S6k1 (S235/236). Cells were sampled on a LSRII Fortessaflow cytometer (BD Biosciences, San Jose, CA), and data analyzed by using FlowJo7.6 software (Tree Star, Ashland, OR).
Western blot. Total protein of cells was extracted and the concentration determined by a BCA Protein Assay kit. Four micrograms of protein was separated electrophoretically by NuPAGE Bis-Tris mini gels (Life Technologies, Carlsbad, CA, USA) and probed with phospho-mTOR, phospho-4EBP1, phospho-STAT3, phosphor-p44/ 42 MAPK, or phosphor-NF-kB p65 Abs overnight, followed by 1 h HRP-conjugated anti-rabbit secondary Ab. Membranes were stripped and re-probed for actin as loading control. Protein/b-actin relative expression was calculated using ImageJ (10.2) software.
Quantitative real-time PCR. Total RNA was extracted with TRIzol (Life Technologies) and quantified for cDNA synthesis. Quantitative real-time PCR reactions were performed by using SYBR Green Gene Expression Assays (Bio-Rad, Hercules, CA, USA). The primers are listed in Supplementary Table 1 . All data were normalized to GAPDH mRNA expression.
Enteroid culture. The intestines were cut longitudinally, minced, and treated with 2 mM EDTA. The tissues were then treated with PBS containing 43.3 mM sucrose and 54.9 mM sorbitol, and filtered through a 70-mm cell strainer. Supernatant was collected and centrifuged. The resulting pellet containing detached crypts was re-suspended in Matrigel (BD Bioscience, San Jose, CA) with 0.5 mg ml À 1 rEGF (R&D Systems, Minneapolis, MN, 2028-EG), 1 mg ml À 1 rNoggin (R&D Systems, cat. no. 1967-NG/CF), 5 mg ml À 1 rR-spondin (R&D Systems, cat. no. 3474-RS), and 1 mg ml À 1 rWnt3a (R&D Systems, cat. no. 35036-WN/CF). In total, 50 ml Matrigel with 500 crypts was plated, and advanced DMEM/F12 media (Invitrogen, Carlsbad, CA, cat. no. 12634-010) with 1 Â N2 supplement (R&D Systems, cat. no. AR009), and 1 Â B27 (Invitrogen, cat. no. 12587-010). Five days later, the enteroids were treated with 0.5 mM butyrate.
16S rRNA pyrosequencing analysis. Fecal bacterial DNA was isolated using a MoBio PowerFecal kit (MoBio, Carlsbad, CA, USA). The isolated DNA was amplified using universal V3-V4 16S rRNA V3-V4 region primers. Sequencing was performed with an Illumina MiSeq instrument. The raw sequencing reads were trimmed and filtered based on initial quality assessment using FASTQC. The reads were trimmed to 350 bases and filtered to exclude reads with low quality, two or more unknown characters, sequencing adapters. To identify the presence of known bacteria, the subsequences were analyzed using CLC Genomics Workbench 8.5 Microbial Genomics Module. Reference-based OTU picking was performed using the SILVA SSU v119 97% database. Sequences present in more than one copy but not clustered to the database were then placed into de novo OTUs (97% similarity) and aligned against the database with 80% similarity threshold using MUSCLE alignment. 
